C3: Architectural tissue reconstruction

The limit comes from oxygen diffusion physics, and it is remarkably hard. Oxygen reaches cells by diffusing out of capillaries through tissue, and the distance it can travel before being consumed is set by the balance between the diffusion rate and the metabolic demand of the cells it passes through.

For metabolically active mammalian tissue, that distance — the maximum a cell can sit from the nearest capillary and still receive enough oxygen — is roughly 100-200 micrometres. This is why capillaries in real tissue are spaced at intervals on that order: every cell must be within a few cell-widths of a blood supply. Tissue thicker than about 1mm without an internal vascular network develops a hypoxic, necrotic core because the cells in the middle are too far from any oxygen source.

This is why tissue engineering can make thin structures (cornea, bladder wall, skin, blood-vessel segments) relatively readily, while thick solid organs (heart, liver, kidney) remain experimental. The thin tissues do not need an internal vascular hierarchy; the thick ones cannot survive without one.

Generating that internal vasculature is not just a matter of adding vessels — it requires a hierarchy: large arteries branching to arterioles branching to capillary beds, then collecting into venules and veins, with the geometry arranged so that every cell in the tissue falls within the diffusion distance of a capillary. Reproducing that branching architecture, with the right vessel calibres and wall structures at each level, is among the hardest unsolved problems in the field.

Each of the three leading approaches wins in a different context, and the leading edge increasingly combines them.

Pre-vascularised scaffolds. Build the vessel network first — by 3D bioprinting hollow channels, by sacrificial templating (printing a vessel-shaped material that is later dissolved away, leaving channels), or by laser-patterning — then seed parenchymal cells around it. This gives precise control over large-vessel geometry but struggles to reproduce the finest capillary-scale structure, which is below current bioprinting resolution. Best for tissues where the large-vessel architecture matters most.

Endothelial co-culture / self-organisation. Include vessel-forming endothelial cells (and supporting pericytes) in the construct and provide the right signalling environment, then let them self-assemble into vessel networks the way they do during development. This produces realistic capillary-scale structure but the resulting network is often chaotic, poorly connected to a defined inlet and outlet, and difficult to perfuse on demand. Best for the fine-scale capillary beds that scaffolding cannot reach.

Decellularised matrix. Take a real organ (often from an animal or a non-transplantable human donor), strip out the original cells with detergents while preserving the extracellular-matrix scaffold — crucially including the entire native vascular tree — then repopulate it with patient-derived cells. This inherits a perfect vascular hierarchy for free but is limited by the supply of donor scaffolds, the difficulty of fully re-endothelialising the preserved vessels, and immune reactions to residual matrix components.

No single approach is winning outright. The leading edge for whole-organ work combines them: decellularised or scaffold-defined large-vessel architecture, with self-organisation filling in the capillary-scale beds. Wake Forest's WFIRM and several academic programmes are advancing this composite strategy, but functional thick solid organs remain experimental rather than clinical.

Most tissue engineering happens ex vivo — build the tissue in a bioreactor, then implant it. AIHS-relevant reconstruction would happen in vivo, rebuilding damaged tissue inside a patient who remains alive and functioning throughout. This changes the problem in both directions.

Advantages of in vivo: The existing host tissue provides templates and signalling cues that guide reconstruction. The host's own vascular system can connect to and supply the developing tissue, potentially solving the vascularisation problem that ex vivo work struggles with. The immune system can be engaged to clear damaged-tissue debris. And reconstruction happens in the correct physiological environment — the right temperature, mechanical loading, biochemical milieu — rather than an artificial bioreactor approximation.

Disadvantages of in vivo: Existing pathological tissue actively interferes. Scar tissue is famously inhibitory to regeneration — the fibrotic, collagen-dense environment that forms after injury suppresses the very regenerative processes reconstruction needs. The host's systemic biology may not support reconstruction: aged patients, or those with the chronic disease that caused the damage in the first place, often have reduced regenerative capacity precisely when they need it most. The immune system may attack the developing tissue rather than supporting it. And — the constraint with no ex vivo analogue — reconstruction must occur in a body that cannot be paused. You cannot stop a beating heart to rebuild it; physiology continues throughout, imposing mechanical and metabolic demands on tissue that is not yet mature enough to bear them.

For AIHS-grade in vivo reconstruction, several capabilities must come together: careful immunomodulation (so the host supports rather than attacks the new tissue), environment-conditioning before reconstruction (clearing inhibitory scar tissue, restoring a permissive milieu), and patient-derived cells to minimise rejection. The integration with B3 matters here — predictive causal models of how a given patient's reconstruction will proceed are needed to plan it — as does C6, the safety architecture that can halt or reverse a reconstruction that begins to go wrong inside a living patient.